Cryptococcus inositol utilization modulates the host protective immune response during brain infection

Cell Communication and Signaling

Volumn 12, Issue 1, 2014, Pages

  Liu, Tong Bao ^a   Subbian, Selvakumar ^a,b   Pan, Weihua ^c   Eugenin, Eliseo ^a,b   Xie, Jianping ^d   Xue, Chaoyang ^a,b  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d SOUTHWEST UNIVERSITY   (China)

Author keywords

Capsule production; Cellular networks; Cryptococcal meningoencephalitis; Cryptococcus neoformans; Genome wide transcriptome; Glucuronoxylomannan; Host immune response; Immune pathways; Inositol transporters; Quantitative real time PCR

Indexed keywords

GLUCURONOXYLOMANNAN; INOSITOL; INTERFERON; TRANSCRIPTOME; GAMMA INTERFERON; POLYSACCHARIDE; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INFECTION; CARBOHYDRATE SYNTHESIS; CELL SURFACE; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DISEASE ASSOCIATION; FUNGAL CAPSULE; FUNGAL VIRULENCE; FUNGUS MUTANT; GENE EXPRESSION PROFILING; GENE ONTOLOGY; GENE REGULATORY NETWORK; GENOME; HOST RESISTANCE; IMMUNOPATHOGENESIS; INTERFERON GAMMA GENE; MOUSE; NONHUMAN; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REGULON; RNA SEQUENCE; SIGNAL TRANSDUCTION; TH1 CELL; TNF ALPHA GENE; VALIDATION STUDY; WILD TYPE; ANIMAL; BRAIN DISEASE; CRYPTOCOCCOSIS; FEMALE; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; METABOLISM; MUTATION; PHYSIOLOGY; SEQUENCE ANALYSIS;

ANIMALS; BRAIN DISEASES; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FEMALE; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; HOST-PATHOGEN INTERACTIONS; INOSITOL; INTERFERON-GAMMA; MICE; MUTATION; POLYSACCHARIDES; REAL-TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, RNA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84908154445     PISSN: None     EISSN: 1478811X     Source Type: Journal    
DOI: 10.1186/s12964-014-0051-0     Document Type: Article

References (50)

1. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM: Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009, 23:525-530.
2. Shi M, Li SS, Zheng C, Jones GJ, Kim KS, Zhou H, Kubes P, Mody CH: Real-time imaging of trapping and urease-dependent transmigration of Cryptococcus neoformans in mouse brain. J Clin Invest 2010, 120:1683-1693.
3. Liu TB, Perlin DS, Xue C: Molecular mechanisms of cryptococcal meningitis. Virulence 2012, 3:173-181.
4. Jong A, Wu CH, Shackleford GM, Kwon-Chung KJ, Chang YC, Chen HM, Ouyang Y, Huang SH: Involvement of human CD44 during Cryptococcus neoformans infection of brain microvascular endothelial cells. Cell Microbiol 2008, 10:1313-1326.
5. Huang SH, Long M, Wu CH, Kwon-Chung KJ, Chang YC, Chi F, Lee S, Jong A: Invasion of Cryptococcus neoformans into human brain microvascular endothelial cells is mediated through the lipid rafts-endocytic pathway via the dual specificity tyrosine phosphorylation-regulated kinase 3 (DYRK3). J Biol Chem 2011, 286:34761-34769.
6. Charlier C, Chretien F, Baudrimont M, Mordelet E, Lortholary O, Dromer F: Capsule structure changes associated with Cryptococcus neoformans crossing of the blood-brain barrier. Am J Pathol 2005, 166:421-432.
7. Vecchiarelli A, Monari C: Capsular material of Cryptococcus neoformans: virulence and much more. Mycopathologia 2012, 173:375-386.
8. Eugenin EA, Greco JM, Frases S, Nosanchuk JD, Martinez LR: Methamphetamine alters blood brain barrier protein expression in mice, facilitating central nervous system infection by neurotropic Cryptococcus neoformans. J Infect Dis 2013, 208:699-704.
9. Liu TB, Kim JC, Wang Y, Toffaletti DL, Eugenin E, Perfect JR, Kim KJ, Xue C: Brain inositol is a novel stimulator for promoting Cryptococcus penetration of the blood-brain barrier. PLoS Pathog 2013, 9:e1003247.
10. Olszewski MA, Noverr MC, Chen GH, Toews GB, Cox GM, Perfect JR, Huffnagle GB: Urease expression by Cryptococcus neoformans promotes microvascular sequestration, thereby enhancing central nervous system invasion. Am J Pathol 2004, 164:1761-1771.
11. Cox GM, Mukherjee J, Cole GT, Casadevall A, Perfect JR: Urease as a virulence factor in experimental cryptococcosis. Infect Immun 2000, 68:443-448.
12. Lee A, Toffaletti DL, Tenor J, Soderblom EJ, Thompson JW, Moseley MA, Price M, Perfect JR: Survival defects of Cryptococcus neoformans mutants exposed to human cerebrospinal fluid result in attenuated virulence in an experimental model of meningitis. Infect Immun 2010, 78:4213-4225.
13. Tseng HK, Liu CP, Price MS, Jong AY, Chang JC, Toffaletti DL, Betancourt-Quiroz M, Frazzitta AE, Cho WL, Perfect JR: Identification of genes from the fungal pathogen Cryptococcus neoformans related to transmigration into the central nervous system. PLoS One 2012, 7:e45083.
14. Vu K, Eigenheer RA, Phinney BS, Gelli A: Cryptococcus neoformans promotes its transmigration into the central nervous system by inducing molecular and cellular changes in brain endothelial cells. Infect Immun 2013, 81: 3139-3147.
15. Xue C, Tada Y, Dong X, Heitman J: The human fungal pathogen Cryptococcus can complete its sexual cycle during a pathogenic association with plants. Cell Host Microbe 2007, 1:263-273.
16. Xue C, Liu T, Chen L, Li W, Liu I, Kronstad JW, Seyfang A, Heitman J: Role of an expanded inositol transporter repertoire in Cryptococcus neoformans sexual reproduction and virulence. mBio 2010, 1:e00084 - 00010.
17. Chen Y, Toffaletti DL, Tenor JL, Litvintseva AP, Fang C, Mitchell TG, McDonald TR, Nielsen K, Boulware DR, Bicanic T, Perfect JR: The Cryptococcus neoformans transcriptome at the site of human meningitis. MBio 2014, 5:e01087-01013.
18. Wang Y, Liu TB, Delmas G, Park S, Perlin D, Xue C: Two major inositol transporters and their role in cryptococcal virulence. Eukaryot Cell 2011, 10:618-628.
19. Jong A, Wu CH, Chen HM, Luo F, Kwon-Chung KJ, Chang YC, Lamunyon CW, Plaas A, Huang SH: Identification and characterization of CPS1 as a hyaluronic acid synthase contributing to the pathogenesis of Cryptococcus neoformans infection. Eukaryot Cell 2007, 6: 1486-1496.
20. Jong A, Wu CH, Gonzales-Gomez I, Kwon-Chung KJ, Chang YC, Tseng HK, Cho WL, Huang SH: Hyaluronic acid receptor CD44 deficiency is associated with decreased Cryptococcus neoformans brain infection. J Biol Chem 2012, 287:15298-15306.
21. Price MS, Perfect JR: Host defenses against cryptococcosis. Immunol Invest 2011, 40:786-808.
22. Voelz K, May RC: Cryptococcal interactions with the host immune system. Eukaryot Cell 2010, 9:835-846.
23. Casadevall A, Pirofski LA: A reappraisal of humoral immunity based on mechanisms of antibody-mediated protection against intracellular pathogens. Adv Immunol 2006, 91:1-44.
24. Kechichian TB, Shea J, Del Poeta M: Depletion of alveolar macrophages decreases the dissemination of a glucosylceramide-deficient mutant of Cryptococcus neoformans in immunodeficient mice. Infect Immun 2007, 75:4792-4798.
25. Del Poeta M: Role of phagocytosis in the virulence of Cryptococcus neoformans. Eukaryot Cell 2004, 3:1067-1075.
26. Bulmer GS, Tacker JR: Phagocytosis of Cryptococcus neoformans by alveolar macrophages. Infect Immun 1975, 11:73-79.
27. Chaturvedi AK, Wormley FL Jr: Cryptococcus antigens and immune responses: implications for a vaccine. Expert Rev Vaccines 2013, 12:1261-1272.
28. Wozniak KL, Hardison S, Olszewski M, Wormley FL Jr: Induction of protective immunity against cryptococcosis. Mycopathologia 2012, 173:387-394.
29. Shoham S, Huang C, Chen JM, Golenbock DT, Levitz SM: Toll-like receptor 4 mediates intracellular signaling without TNF-alpha release in response to Cryptococcus neoformans polysaccharide capsule. J Immunol 2001, 166:4620-4626.
30. Wozniak KL, Ravi S, Macias S, Young ML, Olszewski MA, Steele C, Wormley FL: Insights into the mechanisms of protective immunity against Cryptococcus neoformans infection using a mouse model of pulmonary cryptococcosis. PLoS One 2009, 4:e6854.
31. Zhang Y, Wang F, Tompkins KC, McNamara A, Jain AV, Moore BB, Toews GB, Huffnagle GB, Olszewski MA: Robust Th1 and Th17 immunity supports pulmonary clearance but cannot prevent systemic dissemination of highly virulent Cryptococcus neoformans H99. Am J Pathol 2009, 175:2489-2500.
32. Hill JO, Harmsen AG: Intrapulmonary growth and dissemination of an avirulent strain of Cryptococcus neoformans in mice depleted of CD4+ or CD8+ T cells. J Exp Med 1991, 173:755-758.
33. Huffnagle GB, McNeil LK: Dissemination of C. neoformans to the central nervous system: role of chemokines, Th1 immunity and leukocyte recruitment. J Neurovirol 1999, 5:76-81.
34. Pappas PG, Bustamante B, Ticona E, Hamill RJ, Johnson PC, Reboli A, Aberg J, Hasbun R, Hsu HH: Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis 2004, 189:2185-2191.
35. Wormley FL Jr, Perfect JR, Steele C, Cox GM: Protection against cryptococcosis by using a murine gamma interferon-producing Cryptococcus neoformans strain. Infect Immun 2007, 75:1453-1462.
36. Liu TB, Xue C: Fbp1-mediated ubiquitin-proteasome pathway controls Cryptococcus neoformans virulence by regulating fungal intracellular growth in macrophages. Infect Immun 2014, 82:557-568.
37. Buchanan KL, Doyle HA: Requirement for CD4(+) T lymphocytes in host resistance against Cryptococcus neoformans in the central nervous system of immunized mice. Infect Immun 2000, 68:456-462.
38. Chen GH, McDonald RA, Wells JC, Huffnagle GB, Lukacs NW, Toews GB: The gamma interferon receptor is required for the protective pulmonary inflammatory response to Cryptococcus neoformans. Infect Immun 2005, 73:1788-1796.
39. Diamond RD, May JE, Kane MA, Frank MM, Bennett JE: The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection. J Immunol 1974, 112:2260-2270.
40. Kozel TR, Wilson MA, Pfrommer GS, Schlageter AM: Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins. Infect Immun 1989, 57:1922-1927.
41. Levitz SM, Tabuni A: Binding of Cryptococcus neoformans by human cultured macrophages. Requirements for multiple complement receptors and actin. J Clin Invest 1991, 87:528-535.
42. Zaragoza O, Taborda CP, Casadevall A: The efficacy of complement-mediated phagocytosis of Cryptococcus neoformans is dependent on the location of C3 in the polysaccharide capsule and involves both direct and indirect C3-mediated interactions. Eur J Immunol 2003, 33: 1957-1967.
43. Gates MA, Kozel TR: Differential localization of complement component 3 within the capsular matrix of Cryptococcus neoformans. Infect Immun 2006, 74:3096-3106.
44. Zaragoza O, Rodrigues ML, De Jesus M, Frases S, Dadachova E, Casadevall A: The capsule of the fungal pathogen Cryptococcus neoformans. Adv Appl Microbiol 2009, 68:133-216.
45. O'Meara TR, Alspaugh JA: The Cryptococcus neoformans capsule: a sword and a shield. Clin Microbiol Rev 2012, 25:387-408.
46. Piccioni M, Monari C, Kenno S, Pericolini E, Gabrielli E, Pietrella D, Perito S, Bistoni F, Kozel TR, Vecchiarelli A: A purified capsular polysaccharide markedly inhibits inflammatory response during endotoxic shock. Infect Immun 2013, 81:90-98.
47. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B: Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 2008, 5:621-628.
48. Subbian S, Bandyopadhyay N, Tsenova L, OB P, Khetani V, Kushner NL, Peixoto B, Soteropoulos P, Bader JS, Karakousis PC, Fallows D, Kaplan G: Early innate immunity determines outcome of Mycobacterium tuberculosis pulmonary infection in rabbits. Cell Commun Signal 2013, 11:60.
49. Lyons JL, Gireesh ED, Trivedi JB, Bell WR, Cettomai D, Smith BR, Karram S, Chang T, Tochen L, Zhang SX, McCall CM, Pearce DT, Carroll KC, Chen L, Ratchford JN, Harrison DM, Ostrow LW, Stevens RD: Fatal exserohilum meningitis and central nervous system vasculitis after cervical epidural methylprednisolone injection. Ann Intern Med 2012, 157:835-836.
50. Wozniak KL, Levitz SM: Isolation and purification of antigenic components of Cryptococcus. Methods Mol Biol 2009, 470:71-83.